# US 2024/0197905 A1 · Muscle targeting complexes and uses thereof for treating dystrophinopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197905 A1
- Document ID: US20240197905A1
- Status: Published application
- Kind: A1
- Application number: 18/592,695
- Filed: 2024-03-01
- Published: 2024-06-20
- Earliest claimed: 2021-07-09
- Assignees: Dyne Therapeutics, Inc.
- Applicants: Dyne Therapeutics, Inc.
- Inventors: Romesh R. Subramanian; Mohammed T. Qatanani; Timothy Weeden; Cody A. Desjardins; Brendan Quinn; John Najim
- Web page: https://patentgrep.com/patent/US20240197905A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 16/2881: {against CD71}
- C07K 2317/77: Internalization into the cell
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A composition comprising complexes comprising an anti-transferrin receptor (TfR) antibody covalently linked to at least one oligonucleotide, wherein the antibody is a Fab and comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90, and wherein each anti-TfR antibody of the complexes is on average covalently linked to 1 to 3 oligonucleotides, and wherein the oligonucleotide induces dystrophin exon 45 skipping, wherein the complexes of the composition comprise a structure of:
wherein n is 3 and m is 4, wherein L1 comprises a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, —O—, —N(RA)—, —S—, —C(═O)—, —C(═O)O—, —C(═O)NRA—, —NRAC(═O)—, —NRAC(═O)RA—, —C(═O)RA—, —NRAC(═O)O—, —NRAC(═O)N(RA)—, —OC═—, —O(═O)—, —OC(═O)N(RA)—, —S(O)2NRA—, —NRAS(O)2—, or a combination thereof, wherein each RA is independently hydrogen or substituted or unsubstituted alkyl.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the heavy chain of the antibody comprises an N-terminal pyroglutamate.

### Claim 31 (depends on 29)

The composition of claim 29, wherein the equilibrium dissociation constant (KD) of binding of the antibody to the transferrin receptor is in a range from 10−11 M to 10−6 M.

### Claim 32 (depends on 29)

The composition of claim 29, wherein the oligonucleotide is 15-35 nucleotides in length.

### Claim 33 (depends on 29)

The composition of claim 29, wherein the oligonucleotide comprises a region of complementarity to a dystrophin RNA, wherein the region of complementarity is 12-35 nucleotides in length.

### Claim 34 (depends on 29)

The composition of claim 29, wherein the oligonucleotide comprises a region of complementarity to the target sequence of an oligonucleotide as set forth in any one of SEQ ID NOs: 256-306, 2252, 2255, and 2258, wherein the region of complementarity is 12-35 nucleotides in length.

### Claim 35 (depends on 29)

The composition of claim 29, wherein the oligonucleotide comprises the nucleotide sequence of any one of SEQ ID NOs: 256-306, 2252, 2255, and 2258, wherein any one or more of the thymine bases (T's) in the oligonucleotide may optionally be a uracil base (U), and wherein any one or more of the uracil bases (U's) in the oligonucleotide may optionally be a thymine base (T).

### Claim 36 (depends on 29)

The composition of claim 29, wherein the oligonucleotide comprises one or more modified nucleosides.

### Claim 37 (depends on 29)

The composition of claim 29, wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer.

### Claim 38 (depends on 29)

The composition of claim 29, wherein L1 comprises a structure of:
wherein the piperazine moiety links to the oligonucleotide wherein L2 comprises

### Claim 39 (depends on 38)

The composition of claim 38, wherein L2 comprises

### Claim 40 (depends on 29)

A method of inducing dystrophin exon 45 skipping in muscle cells of a subject, the method comprising administering to the subject the composition of claim 29.

### Claim 41 (depends on 40)

The method of claim 40, wherein the subject is human.

### Claim 42 (depends on 40)

The method of claim 40, wherein the subject is a cynomolgus.

### Claim 43 (depends on 40)

The method of claim 40, wherein the subject expresses a dystrophin pre-mRNA comprising a frameshift mutation.

### Claim 44 (depends on 40)

The method of claim 40, wherein the complex is intravenously administered to the subject.

### Claim 45 (depends on 40)

The method of claim 40, wherein the subject is amenable to dystrophin exon 45 skipping.

### Claim 46 (depends on 40)

The method of claim 40, wherein the subject has Duchenne muscular dystrophy.

### Claim 47 (depends on 40)

The method of claim 40, wherein the heavy chain of the antibody comprises an N-terminal pyroglutamate.
